세계의 섬유근육통 치료 시장 규모, 점유율, 산업 동향 분석 리포트 : 약제 클래스별, 유통 채널별, 지역별 전망과 예측(2023-2030년)

The Global Fibromyalgia Treatment Market size is expected to reach $4 billion by 2030, rising at a market growth of 4.4% CAGR during the forecast period.

Muscle Relaxants are widely utilized by people to ease muscle stiffness or spasms and help in relaxing painful knots. As road accidents are increasing, the usage of muscle relaxant is increasing. Therefore, Muscle relaxants accounted for $202.3 million revenue in 2022. Road traffic accidents kill approximately 1.3 million people annually and injure between 20 and 50 million others, as stated by the WHO report. Over fifty percent of road traffic deaths and injuries involve vulnerable road users, such as pedestrians, motorcyclists, cyclists, and passengers. Children and young adults aged 5 to 29 are disproportionately susceptible to road traffic injuries.

Among people of this age, it is the most common cause of death. Males under 25 are more likely than females to be involved in traffic incidents. According to statistics, males account for 73% of the traffic fatalities in this age group. 93% of road traffic fatalities occur in low- and middle-income countries, increasing road traffic injury rates in developing nations. Consequently, the rise in road accidents due to various factors is anticipated to increase the cases of fibromyalgia, which will raise the need for fibromyalgia treatment, thereby driving market expansion. Some of the factors impacting the market are research for novel drugs and possible uses of combination therapy, Co-relation between lupus and fibromyalgia, and non-drug alternative.

Chronic fibromyalgia substantially limits patients' ability to engage in typical social and professional activities and makes maintaining relationships with friends, family, and coworkers difficult. The full spectrum of pain, tiredness, sleep disturbances, and depression symptoms cannot be fully addressed by any available medicines. The growing need for better and more effective treatment options for FM will spur pharmaceutical companies to continue their research and development efforts, driving the market. Lupus is a common (chronic) autoimmune disorder that can be debilitating and has the potential to affect a variety of body systems. Lupus is developed when the immune system, which typically aids in defending the body against infection and disease, targets its tissues. As a result, it is anticipated that their prevalence will rise along with the number of lupus cases, fueling demand for fibromyalgia treatment options and fueling market expansion.

However, Fibromyalgia can be managed with non-drug alternatives with many benefits while incurring no side effects. One such alternative is stress management. This works by creating a strategy to prevent or reduce overexertion and emotional tension and allowing oneself daily relaxation time. This is expected to hamper the market growth in the projected period. Fibromyalgia is reportedly widespread among those who have recovered from COVID-19, according to a study from the National Center for Biotechnology Information (NCBI). This data suggests that fibromyalgia may be more common among those who have had COVID-19, increasing the need for treatment after the pandemic. Hence, the pandemic caused the market to decline, but later, the market started to recover due to the growing number of FM cases.

Drug Class Outlook

Based on drug class, the market is segmented into antidepressants, anticonvulsants, muscle relaxants and others. The antidepressants segment acquired a substantial revenue share in the market in 2022. This is because there are several antidepressant choices accessible for fibromyalgia patients. Multiple antidepressants are readily available, allowing for greater prescribing flexibility and a greater chance that each patient will receive the right treatment. This market's expansion is also anticipated to be aided by the availability of generic versions of antidepressants approved for use in fibromyalgia patients.

Distribution Channel Outlook

On the basis of distribution channel, the market is divided into hospital pharmacies, drug stores & retail pharmacies and online providers. The drug stores & retail pharmacies segment witnessed the largest revenue share in the market in 2022. The segment growth is due to the presence of drug stores and retail pharmacies in multiple locations in diverse neighborhoods and communities, which are extensively accessible to the general public. This ubiquitous presence guarantees easy access to drugs and treatments for those with fibromyalgia.

Regional Outlook

Region-wise, the market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North America region registered the highest revenue share in the market in 2022. This is due to several variables, including increased fibromyalgia prevalence, new treatment choices, and supporting healthcare infrastructure. A vital healthcare infrastructure, high purchasing power, and increased acceptance of fibromyalgia drugs are anticipated to fuel market expansion. The market in this region is also driven by numerous significant players and developments in manufacturing technology these businesses use to manufacture effective goods.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include AbbVie, Inc., Novartis AG, Eli Lilly And Company, Amneal Pharmaceuticals, Inc., Teva Pharmaceuticals Industries Ltd., Zydus Lifesciences Ltd., Lupin Limited, Abbott Laboratories, Viatris, Inc., and Sun Pharmaceutical Industries Ltd.

Scope of the Study

Market Segments covered in the Report:

By Drug Class

• Anticonvulsants
• Antidepressants
• Muscle Relaxants
• Others

By Distribution Channel

• Drug stores & Retail Pharmacies
• Hospital Pharmacies
• Online Providers

By Geography

• North America
  • US
  • Canada
  • Mexico
  • Rest of North America
• Europe
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific
• LAMEA
  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA

Companies Profiled

• AbbVie, Inc.
• Novartis AG
• Eli Lilly And Company
• Amneal Pharmaceuticals, Inc.
• Teva Pharmaceuticals Industries Ltd.
• Zydus Lifesciences Ltd.
• Lupin Limited
• Abbott Laboratories
• Viatris, Inc.
• Sun Pharmaceutical Industries Ltd.

Unique Offerings from KBV Research

• Exhaustive coverage
• Highest number of market tables and figures
• Subscription based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free

Table of Contents

Chapter 1. Market Scope & Methodology

• 1.1 Market Definition
• 1.2 Objectives
• 1.3 Market Scope
• 1.4 Segmentation
  • 1.4.1 Global Fibromyalgia Treatment Market, by Drug Class
  • 1.4.2 Global Fibromyalgia Treatment Market, by Distribution Channel
  • 1.4.3 Global Fibromyalgia Treatment Market, by Geography
• 1.5 Methodology for the research

Chapter 2. Market Overview

• 2.1 Introduction
  • 2.1.1 Overview
    • 2.1.1.1 Market composition & scenario
• 2.2 Key Factors Impacting the Market
  • 2.2.1 Market Drivers
  • 2.2.2 Market Restraints

Chapter 3. Global Fibromyalgia Treatment Market by Drug Class

• 3.1 Global Anticonvulsants Market by Region
• 3.2 Global Antidepressants Market by Region
• 3.3 Global Muscle Relaxants Market by Region
• 3.4 Global Others Market by Region

Chapter 4. Global Fibromyalgia Treatment Market by Distribution Channel

• 4.1 Global Drug stores & Retail Pharmacies Market by Region
• 4.2 Global Hospital Pharmacies Market by Region
• 4.3 Global Online Providers Market by Region

Chapter 5. Global Fibromyalgia Treatment Market by Region

• 5.1 North America Fibromyalgia Treatment Market
  • 5.1.1 North America Fibromyalgia Treatment Market by Drug Class
    • 5.1.1.1 North America Anticonvulsants Market by Country
    • 5.1.1.2 North America Antidepressants Market by Country
    • 5.1.1.3 North America Muscle Relaxants Market by Country
    • 5.1.1.4 North America Others Market by Country
  • 5.1.2 North America Fibromyalgia Treatment Market by Distribution Channel
    • 5.1.2.1 North America Drug stores & Retail Pharmacies Market by Country
    • 5.1.2.2 North America Hospital Pharmacies Market by Country
    • 5.1.2.3 North America Online Providers Market by Country
  • 5.1.3 North America Fibromyalgia Treatment Market by Country
    • 5.1.3.1 US Fibromyalgia Treatment Market
      • 5.1.3.1.1 US Fibromyalgia Treatment Market by Drug Class
      • 5.1.3.1.2 US Fibromyalgia Treatment Market by Distribution Channel
    • 5.1.3.2 Canada Fibromyalgia Treatment Market
      • 5.1.3.2.1 Canada Fibromyalgia Treatment Market by Drug Class
      • 5.1.3.2.2 Canada Fibromyalgia Treatment Market by Distribution Channel
    • 5.1.3.3 Mexico Fibromyalgia Treatment Market
      • 5.1.3.3.1 Mexico Fibromyalgia Treatment Market by Drug Class
      • 5.1.3.3.2 Mexico Fibromyalgia Treatment Market by Distribution Channel
    • 5.1.3.4 Rest of North America Fibromyalgia Treatment Market
      • 5.1.3.4.1 Rest of North America Fibromyalgia Treatment Market by Drug Class
      • 5.1.3.4.2 Rest of North America Fibromyalgia Treatment Market by Distribution Channel
• 5.2 Europe Fibromyalgia Treatment Market
  • 5.2.1 Europe Fibromyalgia Treatment Market by Drug Class
    • 5.2.1.1 Europe Anticonvulsants Market by Country
    • 5.2.1.2 Europe Antidepressants Market by Country
    • 5.2.1.3 Europe Muscle Relaxants Market by Country
    • 5.2.1.4 Europe Others Market by Country
  • 5.2.2 Europe Fibromyalgia Treatment Market by Distribution Channel
    • 5.2.2.1 Europe Drug stores & Retail Pharmacies Market by Country
    • 5.2.2.2 Europe Hospital Pharmacies Market by Country
    • 5.2.2.3 Europe Online Providers Market by Country
  • 5.2.3 Europe Fibromyalgia Treatment Market by Country
    • 5.2.3.1 Germany Fibromyalgia Treatment Market
      • 5.2.3.1.1 Germany Fibromyalgia Treatment Market by Drug Class
      • 5.2.3.1.2 Germany Fibromyalgia Treatment Market by Distribution Channel
    • 5.2.3.2 UK Fibromyalgia Treatment Market
      • 5.2.3.2.1 UK Fibromyalgia Treatment Market by Drug Class
      • 5.2.3.2.2 UK Fibromyalgia Treatment Market by Distribution Channel
    • 5.2.3.3 France Fibromyalgia Treatment Market
      • 5.2.3.3.1 France Fibromyalgia Treatment Market by Drug Class
      • 5.2.3.3.2 France Fibromyalgia Treatment Market by Distribution Channel
    • 5.2.3.4 Russia Fibromyalgia Treatment Market
      • 5.2.3.4.1 Russia Fibromyalgia Treatment Market by Drug Class
      • 5.2.3.4.2 Russia Fibromyalgia Treatment Market by Distribution Channel
    • 5.2.3.5 Spain Fibromyalgia Treatment Market
      • 5.2.3.5.1 Spain Fibromyalgia Treatment Market by Drug Class
      • 5.2.3.5.2 Spain Fibromyalgia Treatment Market by Distribution Channel
    • 5.2.3.6 Italy Fibromyalgia Treatment Market
      • 5.2.3.6.1 Italy Fibromyalgia Treatment Market by Drug Class
      • 5.2.3.6.2 Italy Fibromyalgia Treatment Market by Distribution Channel
    • 5.2.3.7 Rest of Europe Fibromyalgia Treatment Market
      • 5.2.3.7.1 Rest of Europe Fibromyalgia Treatment Market by Drug Class
      • 5.2.3.7.2 Rest of Europe Fibromyalgia Treatment Market by Distribution Channel
• 5.3 Asia Pacific Fibromyalgia Treatment Market
  • 5.3.1 Asia Pacific Fibromyalgia Treatment Market by Drug Class
    • 5.3.1.1 Asia Pacific Anticonvulsants Market by Country
    • 5.3.1.2 Asia Pacific Antidepressants Market by Country
    • 5.3.1.3 Asia Pacific Muscle Relaxants Market by Country
    • 5.3.1.4 Asia Pacific Others Market by Country
  • 5.3.2 Asia Pacific Fibromyalgia Treatment Market by Distribution Channel
    • 5.3.2.1 Asia Pacific Drug stores & Retail Pharmacies Market by Country
    • 5.3.2.2 Asia Pacific Hospital Pharmacies Market by Country
    • 5.3.2.3 Asia Pacific Online Providers Market by Country
  • 5.3.3 Asia Pacific Fibromyalgia Treatment Market by Country
    • 5.3.3.1 China Fibromyalgia Treatment Market
      • 5.3.3.1.1 China Fibromyalgia Treatment Market by Drug Class
      • 5.3.3.1.2 China Fibromyalgia Treatment Market by Distribution Channel
    • 5.3.3.2 Japan Fibromyalgia Treatment Market
      • 5.3.3.2.1 Japan Fibromyalgia Treatment Market by Drug Class
      • 5.3.3.2.2 Japan Fibromyalgia Treatment Market by Distribution Channel
    • 5.3.3.3 India Fibromyalgia Treatment Market
      • 5.3.3.3.1 India Fibromyalgia Treatment Market by Drug Class
      • 5.3.3.3.2 India Fibromyalgia Treatment Market by Distribution Channel
    • 5.3.3.4 South Korea Fibromyalgia Treatment Market
      • 5.3.3.4.1 South Korea Fibromyalgia Treatment Market by Drug Class
      • 5.3.3.4.2 South Korea Fibromyalgia Treatment Market by Distribution Channel
    • 5.3.3.5 Singapore Fibromyalgia Treatment Market
      • 5.3.3.5.1 Singapore Fibromyalgia Treatment Market by Drug Class
      • 5.3.3.5.2 Singapore Fibromyalgia Treatment Market by Distribution Channel
    • 5.3.3.6 Malaysia Fibromyalgia Treatment Market
      • 5.3.3.6.1 Malaysia Fibromyalgia Treatment Market by Drug Class
      • 5.3.3.6.2 Malaysia Fibromyalgia Treatment Market by Distribution Channel
    • 5.3.3.7 Rest of Asia Pacific Fibromyalgia Treatment Market
      • 5.3.3.7.1 Rest of Asia Pacific Fibromyalgia Treatment Market by Drug Class
      • 5.3.3.7.2 Rest of Asia Pacific Fibromyalgia Treatment Market by Distribution Channel
• 5.4 LAMEA Fibromyalgia Treatment Market
  • 5.4.1 LAMEA Fibromyalgia Treatment Market by Drug Class
    • 5.4.1.1 LAMEA Anticonvulsants Market by Country
    • 5.4.1.2 LAMEA Antidepressants Market by Country
    • 5.4.1.3 LAMEA Muscle Relaxants Market by Country
    • 5.4.1.4 LAMEA Others Market by Country
  • 5.4.2 LAMEA Fibromyalgia Treatment Market by Distribution Channel
    • 5.4.2.1 LAMEA Drug stores & Retail Pharmacies Market by Country
    • 5.4.2.2 LAMEA Hospital Pharmacies Market by Country
    • 5.4.2.3 LAMEA Online Providers Market by Country
  • 5.4.3 LAMEA Fibromyalgia Treatment Market by Country
    • 5.4.3.1 Brazil Fibromyalgia Treatment Market
      • 5.4.3.1.1 Brazil Fibromyalgia Treatment Market by Drug Class
      • 5.4.3.1.2 Brazil Fibromyalgia Treatment Market by Distribution Channel
    • 5.4.3.2 Argentina Fibromyalgia Treatment Market
      • 5.4.3.2.1 Argentina Fibromyalgia Treatment Market by Drug Class
      • 5.4.3.2.2 Argentina Fibromyalgia Treatment Market by Distribution Channel
    • 5.4.3.3 UAE Fibromyalgia Treatment Market
      • 5.4.3.3.1 UAE Fibromyalgia Treatment Market by Drug Class
      • 5.4.3.3.2 UAE Fibromyalgia Treatment Market by Distribution Channel
    • 5.4.3.4 Saudi Arabia Fibromyalgia Treatment Market
      • 5.4.3.4.1 Saudi Arabia Fibromyalgia Treatment Market by Drug Class
      • 5.4.3.4.2 Saudi Arabia Fibromyalgia Treatment Market by Distribution Channel
    • 5.4.3.5 South Africa Fibromyalgia Treatment Market
      • 5.4.3.5.1 South Africa Fibromyalgia Treatment Market by Drug Class
      • 5.4.3.5.2 South Africa Fibromyalgia Treatment Market by Distribution Channel
    • 5.4.3.6 Nigeria Fibromyalgia Treatment Market
      • 5.4.3.6.1 Nigeria Fibromyalgia Treatment Market by Drug Class
      • 5.4.3.6.2 Nigeria Fibromyalgia Treatment Market by Distribution Channel
    • 5.4.3.7 Rest of LAMEA Fibromyalgia Treatment Market
      • 5.4.3.7.1 Rest of LAMEA Fibromyalgia Treatment Market by Drug Class
      • 5.4.3.7.2 Rest of LAMEA Fibromyalgia Treatment Market by Distribution Channel

Chapter 6. Company Profiles

• 6.1 Abbott Laboratories
  • 6.1.1 Company Overview
  • 6.1.2 Financial Analysis
  • 6.1.3 Segmental and Regional Analysis
  • 6.1.4 Research & Development Expense
  • 6.1.5 SWOT Analysis
• 6.2 AbbVie, Inc.
  • 6.2.1 Company Overview
  • 6.2.2 Financial Analysis
  • 6.2.3 Regional Analysis
  • 6.2.4 Research & Development Expense
  • 6.2.5 Recent strategies and developments:
    • 6.2.5.1 Acquisition and Mergers:
• 6.3 Novartis AG
  • 6.3.1 Company Overview
  • 6.3.2 Financial Analysis
  • 6.3.3 Segmental and Regional Analysis
  • 6.3.4 Research & Development Expense
  • 6.3.5 Recent strategies and developments:
    • 6.3.5.1 Acquisition and Mergers:
• 6.4 Eli Lilly And Company
  • 6.4.1 Company Overview
  • 6.4.2 Financial Analysis
  • 6.4.3 Regional Analysis
  • 6.4.4 Research & Development Expenses
• 6.5 Amneal Pharmaceuticals, Inc.
  • 6.5.1 Company Overview
  • 6.5.2 Financial Analysis
  • 6.5.3 Segmental Analysis
  • 6.5.4 Research & Development Expenses
• 6.6 Teva Pharmaceutical Industries Ltd.
  • 6.6.1 Company Overview
  • 6.6.2 Financial Analysis
  • 6.6.3 Regional Analysis
  • 6.6.4 Research & Development Expenses
• 6.7 Zydus Lifesciences Ltd.
  • 6.7.1 Company Overview
  • 6.7.2 Financial Analysis
  • 6.7.3 Segmental and Regional Analysis
  • 6.7.4 Research & Development Expense
  • 6.7.5 Recent strategies and developments:
    • 6.7.5.1 Trials and Approvals:
• 6.8 Lupin Limited
  • 6.8.1 Company Overview
  • 6.8.2 Financial Analysis
  • 6.8.3 Recent strategies and developments:
    • 6.8.3.1 Trials and Approvals:
• 6.9 Viatris, Inc.
  • 6.9.1 Company Overview
  • 6.9.2 Financial Analysis
  • 6.9.3 Segmental Analysis
  • 6.9.4 Research & Development Expense
• 6.10. Sun Pharmaceutical Industries Ltd.
  • 6.10.1 Company Overview
  • 6.10.2 Financial Analysis
  • 6.10.3 Regional Analysis
  • 6.10.4 Research & Development Expenses